Related Experiment Video

Updated: Sep 7, 2025

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles
09:00

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles

Published on: March 18, 2015

11.7K

Application of Transcription Factor Decoy Oligodeoxynucleotides (ODNs) for Cancer Therapy

Behrooz Johari1,2, Mohammad Moradi3,4

  • 1Department of Medical Biotechnology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran. Dr.johari@zums.ac.ir.

Methods in Molecular Biology (Clifton, N.J.)
|June 22, 2022
PubMed

Insights

Decoy oligodeoxynucleotides (ODNs) offer a gene therapy approach to inhibit cancer stemness by blocking key transcription factors. This method enhances other cancer therapies and shows promise for clinical applications with nanocarrier improvements.

Area of Science:

  • Molecular Biology
  • Gene Therapy
  • Cancer Research

Background:

  • Cancer stemness properties are regulated by transcription factors like MYC, OCT4, SOX2, STAT3, and NANOG.
  • Targeting these transcription factors can inhibit cancer cell differentiation and enhance therapeutic outcomes.

Purpose of the Study:

  • To review the application of decoy oligodeoxynucleotides (ODNs) as a gene therapy strategy for cancer.
  • To highlight the potential of decoy ODNs in combination with other cancer therapies and nanocarriers.

Main Methods:

  • Decoy ODNs function at the pre-transcriptional level by sequestering transcription factors.
  • This inhibition prevents transcription factors from binding to genomic DNA, thereby blocking their activity.

Main Results:

  • Decoy ODNs have demonstrated efficacy against various malignancies by targeting stemness pathways.
  • A synergistic effect is observed when decoy ODNs are combined with conventional anticancer therapies.
  • Nanocarrier technology enhances the delivery and efficacy of decoy ODNs, improving clinical potential.

Conclusions:

  • Decoy ODNs represent a promising gene therapy approach for cancer treatment by targeting essential transcription factors.
  • The combination of decoy ODNs with nanocarriers offers a strategy to improve cancer therapy outcomes and clinical applicability.
Keywords:
Cancer therapyDecoy ODNsDifferentiation therapyGene regulationTranscription factors

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

623
A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers10:49

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers

Published on: September 26, 2019

5.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.2K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.0K
Types of RNA01:20

Types of RNA

Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...
6.2K